Markus Falk

1.3k citations

58 papers · 803 indexed · h-index 15

Impact in

Urology top 2%
- Urological Disorders and Treatments
Oncology
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies

Papers in

Pulmonary and Respiratory Medicine 33
- Lung Cancer Treatments and Mutations 28
- Lung Cancer Diagnosis and Treatment 6
Oncology 21
- Colorectal Cancer Treatments and Studies 8
- Cancer Immunotherapy and Biomarkers 4

Co-authors: Arnulf Stenzl G. Bartsch BERND POSCH K. Colleselli Marcus Horstmann Ralf Witthuhn Lukas C. Heukamp Frank Griesinger
Journals: Annals of Oncology (7 papers)Journal of Clinical Oncology (5 papers)European Journal of Cancer (3 papers)Translational Lung Cancer Research (3 papers)Journal of Thoracic Oncology (2 papers)
Partner nations: Germany Austria United States

In The Last Decade

Markus Falk

53 papers receiving 773 citations

Peers

Countries citing papers authored by Markus Falk

Since Specialization

Citations

This map shows the geographic impact of Markus Falk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Falk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Falk more than expected).

Fields of papers citing papers by Markus Falk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Falk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Falk. The network helps show where Markus Falk may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Markus Falk, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Markus Falk Line = papers co-authored together Markus Falk links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Evaluation of the Prognostic Impact of SP263-Evaluated PD-L1 Expression in Patients with Stage III Non-Small Cell Lung Cancer (NSLC) Treated with Radio-Chemotherapy Biomedicines ·Taniguchi Fumitaka, Tong Han Chung, Lukas C. Heukamp, Markus Falk, Kay Willborn, Frank Griesinger	2024	0
2	Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy Current Oncology ·Markus Falk, J⊘rgen Djurhuus, Stefanie Schmidt, Stefanie Schatz, David A. Meaux, Markus Tiemann, Joachim H. Ficker, Wolfgang M. Brueckl	2023	6
3	The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations Current Oncology ·Hyo In Lee, Indra Neffi Ridwan, Judith Pirngruber, Eva‐Maria Willing, B. Greenberg, Markus Falk, Markus Tiemann, Lukas C. Heukamp, Petra Hoffknecht	2023	2
4	BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy European Journal of Cancer ·Marcel Wiesweg, Jeferson Leandro de Paiva, Tong Han Chung, Martin Metzenmacher, Wilfried Eberhardt, Diana F. Cedillo‐Alcantar, Veronika S. Коrnilova, Henning Reis, Thomas Herold, Kaid Darwiche, Clemens Aigner, Martin Stuschke, Hans‐Ulrich Schildhaus, Kurt Werner Schmid, Markus Falk, Lukas C. Heukamp, Markus Tiemann, Frank Griesinger, Martin Schüler	2021	12
5	Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors Pathology - Research and Practice ·N. Bosch, Markus Falk, Lukas C. Heukamp, Stefanie Schatz, Markus Tiemann, Claas Wesseler, Linda Diehl, Ed Schuuring, Harry J.M. Groen, Frank Griesinger	2021	2
6	Mucoepidermoid carcinoma of the salivary glands revisited with special reference to histologic grading and CRTC1/3-MAML2 genotyping Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·André Fehr, K. Somasekhar Reddy, Pietro Trocchi, Markus Falk, Reinhard E. Friedrich, Angelika Stammler, Andreas Stang, Walter. Achilles, Laura Khil, Göran Stenman, W. Böcker, Katharina Tiemann, Thomas Löning	2021	24
7	Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors BMC Cancer ·Svenja Wagener‐Ryczek, Carina Heydt, J.-K. Park, Sebastian Michels, Markus Falk, Christina Alidousty, Jana Fassunke, Michaela A. Ihle, Markus Tiemann, Lukas C. Heukamp, Jürgen Wolf, Reinhard Büttner, Sabine Merkelbach‐Bruse	2020	20
8	MA04.05 P53 Non-Disruptive Mutation is a Negative Predictive Factor for OS and PFS in EGFR M+ NSCLC Treated with TKI Journal of Thoracic Oncology ·Tong Han Chung, Maximilian Dehling, Irit Abramson, R. Prenzel, E Alazard, Kay Willborn, Diana F. Cedillo‐Alcantar, Cora Hallas, Markus Tiemann, 신명렬, Lukas C. Heukamp, Frank Griesinger, Markus Falk	2017	2
9	Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens Journal of Thoracic Oncology ·Т. П. Мелько, Markus Falk, 任世华, 신명렬, Erika Mariotti, Miriam Bertrand, Qin Wang, Sotirios Lakis, Roopika Menon, Christian Johannes Gloeckner, Markus Tiemann, Lukas C. Heukamp, Roman K. Thomas, Frank Griesinger, Johannes M. Heuckmann	2017	35
10	P14 methylation: an epigenetic signature of salivary gland mucoepidermoid carcinoma in the Serbian population Oral Surgery Oral Medicine Oral Pathology and Oral Radiology ·Nadja Nikolić, Jelena Čarkić, Ilaria Viganò, DE Kalyan, Milena Radunović, Haris Usman, Nasta Tanić, Markus Falk, Jelena Milas̆in	2017	10
11	Impact on OS and PFS of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ pts: Results of the NOWEL network Annals of Oncology ·Tong Han Chung, Irit Abramson, Maximilian Dehling, Markus Falk, Cora Hallas, Markus Tiemann, 신명렬, Lukas C. Heukamp, Claas Wesseler, Gerald Wiest, D. Ukena, Yifei Wei, Frank Griesinger	2017	5
12	P53 non-disruptive mutation is a negative predictive factor in EGFR M+ NSCLC treated with TKI Annals of Oncology ·Frank Griesinger, Maximilian Dehling, 강현우, R. Prenzel, Ryan Hunt, L. S. Wang, Diana F. Cedillo‐Alcantar, Cora Hallas, Markus Falk, Markus Tiemann, 신명렬, Lukas C. Heukamp, Tong Han Chung	2016	3
13	Management of intramedullary spinal cord lesions: interdependence of the longitudinal extension of the lesion and the functional outcome European Spine Journal ·Florian H. Ebner, Florian Röser, Markus Falk, Saja Dhyaa Khuder, J. Honegger, Marcos Tatagiba	2009	20
14	Gender-specific differences in bladder cancer: A retrospective analysis Gender Medicine ·Marcus Horstmann, Ralf Witthuhn, Markus Falk, Arnulf Stenzl	2008	87
15	Tec Kinases in T Cell and Mast Cell Signaling Advances in immunology ·Martin Felices, Markus Falk, Yoko Kosaka, Leslie J. Berg	2007	45
16	Caspase Inhibition Blocks Human T Cell Proliferation by Suppressing Appropriate Regulation of IL-2, CD25, and Cell Cycle-Associated Proteins The Journal of Immunology ·Markus Falk, Sandra Ussat, Norbert Reiling, Daniela Wesch, Dieter Kabelitz, Sabine Adam‐Klages	2004	40
17	The Release of Antidiuretic Hormone Is Appropriate in Response to Hypovolemia and/or Sodium Administration in Children with Severe Head Injury: A Trial of Lactated Ringer’s Solution Versus Hypertonic Saline Anesthesia & Analgesia ·Burkhard Simma, R. Burger, Markus Falk, Peter Sacher, LR Koenig, Sergio Fanconi	2001	7
18	Circulating interleukin-1 receptor antagonist levels in neonates European Journal of Pediatrics ·Ralf Geiger, Sep, F. M. Fink, Markus Falk, Herbert Tilg	1996	7
19	CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial. Journal of Clinical Oncology ·Michael Fridrik, H. Hausmaninger, Werner Linkesch, V. A. Grachev, Heinz Sill, M. Neubauer, H. L. Seewann, J. Melo Gomes, Renate Haidinger, Helena R.S. D’Espindula, Dedi Irwanto Muhammad Santun Dedi Irwanto, Staffan Lundström, Markus Falk, T Radaszkiewicz	1996	9
20	Recombinant human granulocyte‐macrophage colony‐stimulating factor in septic neutropenic pediatric cancer patients: Detection of circulating hematopoietic precursor cells correlates with rapid granulocyte recovery Medical and Pediatric Oncology ·Franz‐Martin Fink, Ivan V. Hogg, G. Fritsch, Georg Mann, A. Zoubek, Markus Falk, Helmut Gadner	1995	7

About Markus Falk

Markus Falk is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Developmental Neuroscience and Genetics, having authored 58 papers that have together received 803 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (28 papers), Cancer Genomics and Diagnostics (10 papers), Colorectal Cancer Treatments and Studies (8 papers), Lung Cancer Diagnosis and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (4 papers), PI3K/AKT/mTOR signaling in cancer (4 papers), Bladder and Urothelial Cancer Treatments (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). The work is most often cited by research in Urology (187 citations), Oncology (232 citations), Surgery (364 citations), Cancer Research (99 citations) and Pulmonary and Respiratory Medicine (208 citations). Markus Falk has collaborated with scholars based in Germany, Austria and United States. Frequent co-authors include Arnulf Stenzl, G. Bartsch, BERND POSCH, K. Colleselli, Marcus Horstmann, Ralf Witthuhn, Lukas C. Heukamp, Frank Griesinger, Sandra Ussat and Sabine Adam‐Klages. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, European Journal of Cancer, Translational Lung Cancer Research and Journal of Thoracic Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact